Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Polaris Capital Management LLC

Polaris Capital Management LLC lowered its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 15.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 432,466 shares of the specialty pharmaceutical company’s stock after selling 81,000 shares during the period. Jazz Pharmaceuticals comprises 6.1% of Polaris Capital Management LLC’s portfolio, making the stock its 2nd largest holding. Polaris Capital Management LLC’s holdings in Jazz Pharmaceuticals were worth $73,519,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC grew its holdings in shares of Jazz Pharmaceuticals by 9.0% during the third quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 81 shares in the last quarter. Tectonic Advisors LLC grew its holdings in shares of Jazz Pharmaceuticals by 1.5% during the third quarter. Tectonic Advisors LLC now owns 5,626 shares of the specialty pharmaceutical company’s stock worth $742,000 after buying an additional 82 shares in the last quarter. Fairbanks Capital Management Inc. grew its holdings in shares of Jazz Pharmaceuticals by 0.4% during the third quarter. Fairbanks Capital Management Inc. now owns 25,023 shares of the specialty pharmaceutical company’s stock worth $3,298,000 after buying an additional 94 shares in the last quarter. Blair William & Co. IL grew its holdings in Jazz Pharmaceuticals by 5.0% in the third quarter. Blair William & Co. IL now owns 2,107 shares of the specialty pharmaceutical company’s stock valued at $278,000 after purchasing an additional 101 shares during the period. Finally, Blue Trust Inc. grew its holdings in Jazz Pharmaceuticals by 3.5% in the third quarter. Blue Trust Inc. now owns 3,261 shares of the specialty pharmaceutical company’s stock valued at $430,000 after purchasing an additional 109 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on JAZZ shares. Morgan Stanley boosted their target price on shares of Jazz Pharmaceuticals from $225.00 to $226.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Bank of America boosted their target price on shares of Jazz Pharmaceuticals from $263.00 to $275.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Wells Fargo & Company boosted their target price on shares of Jazz Pharmaceuticals from $235.00 to $250.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Barclays boosted their target price on shares of Jazz Pharmaceuticals from $224.00 to $225.00 and gave the company an “overweight” rating in a report on Monday. Finally, TD Cowen restated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $216.87.

Jazz Pharmaceuticals Trading Down 1.7%

NASDAQ JAZZ opened at $196.52 on Friday. The company’s fifty day simple moving average is $186.94 and its 200-day simple moving average is $168.80. Jazz Pharmaceuticals PLC has a 52 week low of $97.50 and a 52 week high of $207.48. The company has a current ratio of 1.86, a quick ratio of 1.67 and a debt-to-equity ratio of 1.00. The stock has a market cap of $12.10 billion, a P/E ratio of -32.92, a PEG ratio of 0.35 and a beta of 0.23.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Wednesday, February 25th. The specialty pharmaceutical company reported $6.64 EPS for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The business had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the previous year, the company posted $6.51 earnings per share. The business’s revenue for the quarter was up 8.1% compared to the same quarter last year. Equities research analysts predict that Jazz Pharmaceuticals PLC will post 20.65 EPS for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 55,600 shares of the business’s stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $191.56, for a total transaction of $10,650,736.00. Following the transaction, the executive vice president directly owned 56,862 shares of the company’s stock, valued at approximately $10,892,484.72. The trade was a 49.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Mary Elizabeth Henderson sold 5,343 shares of the business’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $194.49, for a total transaction of $1,039,160.07. Following the transaction, the senior vice president directly owned 28,728 shares in the company, valued at approximately $5,587,308.72. The trade was a 15.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 74,015 shares of company stock valued at $14,180,486. 4.30% of the stock is owned by company insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.